# Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

> **NCT05684731** · PHASE1 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** KM1
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05684731
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05684731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05684731, "Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05684731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*